SMMT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 41 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 85%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 87 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where SMMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
SMMT moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 244 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 148 cases where SMMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.046) is normal, around the industry mean (2.988). P/E Ratio (-14.261) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 220 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SNDX's P/B Ratio (77.770) is slightly higher than the industry average of (2.988). P/E Ratio (-5.239) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SMMT | SNDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 93 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 71 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 84 | |
P/E GROWTH RATING 1..100 | 61 | 12 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SMMT's Valuation (90) in the Biotechnology industry is in the same range as SNDX (95). This means that SMMT’s stock grew similarly to SNDX’s over the last 12 months.
SMMT's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as SNDX (100). This means that SMMT’s stock grew similarly to SNDX’s over the last 12 months.
SMMT's SMR Rating (100) in the Biotechnology industry is in the same range as SNDX (100). This means that SMMT’s stock grew similarly to SNDX’s over the last 12 months.
SMMT's Price Growth Rating (62) in the Biotechnology industry is in the same range as SNDX (84). This means that SMMT’s stock grew similarly to SNDX’s over the last 12 months.
SNDX's P/E Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for SMMT (61). This means that SNDX’s stock grew somewhat faster than SMMT’s over the last 12 months.
| SMMT | SNDX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 86% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 83% | 9 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 77% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SMMT’s FA Score shows that 0 FA rating(s) are green while SNDX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SMMT’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).
SMMT (@Biotechnology) experienced а +4.63% price change this week, while SNDX (@Biotechnology) price change was -2.81% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
SMMT is expected to report earnings on Mar 18, 2027.
SNDX is expected to report earnings on Nov 02, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.